Account
Watchlists
Bookmarks
Pricing
Investor Presentation
Q2 FY21
Investor Presentation
Q4 FY20
Investor Presentation
Q4 FY18
Investor Presentation
Q3 FY18
Investor Presentation
Q2 FY18
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
185.85 | 59 Cr | 13.04 | 1.51 | 1.08 | 11.58 | 14.72 | 9.41 | |
58.19 | 59 Cr | — | 3.24 | 0.00 | -30.18 | -32.45 | -30.18 | |
9.79 | 49 Cr | 97.90 | 0.87 | 0.00 | 0.87 | -11.71 | -50.52 | |
32.72 | 43 Cr | — | 0.72 | 0.00 | -20.68 | -5.35 | -5.02 | |
44.25 | 42 Cr | 17.84 | 2.51 | 0.00 | 13.13 | 15.92 | 5.36 | |
25.24 | 40 Cr | — | 0.33 | 0.00 | -15.52 | -2.61 | -6.25 | |
43.22 | 40 Cr | — | 2.80 | 0.00 | -117.41 | -22.41 | -18.44 |
Bearish
4
Neutral
4
Bullish
6
Bearish
36
Neutral
4
Bullish
6
Bearish
32
Neutral
0
Bullish
0
Market Cap
₹ 47 Cr
P/E
94.30
Lasa Supergenerics Limited is engaged in manufacturing, trading, and producing chemicals, pharmaceuticals, and veterinary APIs, with comprehensive capabilities in research, production, and marketing.
The company specializes in catalyst chemistry and is among India's largest producers of anthelmintic and veterinary API products, with significant production capacity at its facilities in Maharashtra.
Lasa's strategic amalgamation with Harishree Aromatics and Chemicals Pvt. Ltd. strengthens its manufacturing capabilities and market reach, approved by the National Company Law Tribunal in late 2022.
The company has launched two new high-demand veterinary products and is expanding capacity at its Chiplun unit, aiming to capture significant market share globally.
With a WHO Certificate of Good Manufacturing Practices, Lasa is positioned as a key player in the animal healthcare sector with robust global alliances.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
47 Cr
Moderate Risk
94.3
30.8
2.2
0.8
31.40
8.21
Sales CAGR
1Y
-19.47%
3Y
-19.82%
5Y
-9.26%
10Y
—
Profit CAGR
1Y
43.73%
3Y
—
5Y
—
10Y
—
ROE
TTM
0.87%
3Y
-17.62%
5Y
-5.83%
10Y
—
ROCE
TTM
-11.71%
3Y
-15.84%
5Y
-2.40%
10Y
—
Performance
UNDER PERFORMER
Valuation
REASONABLE
Growth
SLUGGISH
Profitability
LOW MARGIN
Technicals
Bearish
Risk
HIGH RISK
Change in Directors/KMP
12 hours ago
Appointment of Company Secretary and Compliance Officer
Mrs. Mitti Jain has been appointed as the Company Secretary and Compliance Officer of Lasa Supergenerics Limited, effective December 16, 2025.
Change in Directors/KMP
4 days ago
Resignation of Whole-time Director
Mr. Prathmesh Chalke has resigned as Whole-time Director of the Company effective December 31, 2025.
